Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel Free DRIO Stock Alerts

DarioHealth (DRIO) Financials

DarioHealth logo
$6.79 +0.04 (+0.59%)
As of 07/16/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for DarioHealth

Annual Income Statements for DarioHealth

This table shows DarioHealth's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -7.30 -12 -16 -18 -21 -33 -79 -64 -64 -41 -62
Consolidated Net Income / (Loss)		 -7.14 -11 -16 -18 -18 -29 -77 -62 -59 -43 -42
Net Income / (Loss) Continuing Operations		 -7.14 -11 -16 -18 -18 -29 -77 -62 -59 -43 -42
Total Pre-Tax Income 		-7.14 -11 -16 -18 -18 -29 -77 -62 -59 -45 -42
Total Operating Income		 -7.70 -11 -14 -18 -18 -30 -76 -57 -56 -58 -37
Total Gross Profit		 -0.86 -0.83 1.31 1.77 2.60 2.51 3.96 9.66 5.98 13 13
Total Revenue		 0.82 2.80 5.17 7.39 7.56 7.58 21 28 20 27 22
Operating Revenue		 0.82 2.80 5.17 7.39 7.56 7.58 21 28 20 27 22
Total Cost of Revenue		 1.68 3.63 3.86 5.63 4.96 5.06 17 18 14 14 9.69
Operating Cost of Revenue		 1.68 3.36 3.86 5.63 4.96 5.06 17 18 14 14 9.69
Total Operating Expenses		 6.84 10 16 19 20 32 80 66 62 71 49
Selling, General & Admin Expense		 2.95 3.38 4.73 5.47 5.48 13 24 16 18 20 15
Marketing Expense		 1.33 4.74 7.71 10 11 15 40 30 24 26 20
Research & Development Expense		 2.57 2.15 3.30 3.68 3.69 4.43 17 20 20 24 14
Total Other Income / (Expense), net		 0.56 0.21 -1.32 -0.12 0.00 0.46 0.00 -5.38 -3.17 13 -4.95
Interest Expense		 - - - - - - - - - 0.00 3.02
Other Income / (Expense), net		 0.56 0.21 -1.32 -0.12 - 0.46 - -5.38 -3.17 13 -1.93
Income Tax Expense		 - - - - - 0.00 0.03 0.00 0.06 -1.85 0.11
Preferred Stock Dividends Declared		 0.15 0.71 0.26 0.49 3.16 3.66 2.01 1.64 4.08 -1.77 20
Basic Earnings per Share		 ($3.84) ($2.09) ($1.64) ($15.63) ($8.00) ($4.01) ($4.07) ($2.54) ($1.93) $12.27 $10.12
Weighted Average Basic Shares Outstanding		 1.90M 5.20M 9.63M 1.17M 2.27M 5.96M 16.59M 23.64M 28.37M 2.45M 3.98M
Diluted Earnings per Share		 ($3.84) ($2.09) ($1.64) ($15.63) ($8.00) ($4.01) ($4.07) ($2.54) ($1.93) $12.27 $10.12
Weighted Average Diluted Shares Outstanding		 1.90M 5.20M 9.63M 1.17M 2.27M 5.96M 16.59M 23.64M 28.37M 2.45M 3.98M
Weighted Average Basic & Diluted Shares Outstanding		 1.90M 5.20M 9.63M 1.17M 2.27M 5.96M 21.81M 25.87M 29.44M 41.57M 7.30M

Quarterly Income Statements for DarioHealth

This table shows DarioHealth's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -17 -16 -9.21 -4.90 -15 -12 -14 -19 -19 -10 -8.25
Consolidated Net Income / (Loss)		 -16 -14 -7.18 -14 -12 -9.63 -9.23 -13 -10 -9.03 -8.25
Net Income / (Loss) Continuing Operations		 -16 -14 -7.18 -14 -12 -9.63 -9.23 -13 -10 -9.03 -7.31
Total Pre-Tax Income 		-16 -14 -9.17 -14 -12 -9.48 -9.21 -13 -10 -8.95 -7.31
Total Operating Income		 -16 -14 -18 -16 -12 -12 -9.41 -9.20 -9.48 -8.56 -7.31
Total Gross Profit		 0.61 0.13 2.43 2.76 3.88 4.20 3.88 2.96 3.02 2.80 3.20
Total Revenue		 3.52 3.62 5.76 6.26 7.42 7.60 6.75 5.37 5.01 5.23 5.58
Operating Revenue		 3.52 3.62 5.76 6.26 7.42 7.60 6.75 5.37 5.01 5.23 5.58
Total Cost of Revenue		 2.91 3.48 3.33 3.50 3.55 3.40 2.87 2.41 1.99 2.43 2.38
Operating Cost of Revenue		 2.91 3.48 3.33 3.50 3.55 3.40 2.87 2.41 1.99 2.43 2.38
Total Operating Expenses		 16 14 20 19 16 16 13 12 12 11 11
Selling, General & Admin Expense		 4.13 5.53 6.74 5.01 3.73 5.01 3.31 3.21 4.57 4.10 3.23
Marketing Expense		 6.36 4.62 6.91 7.13 6.73 5.58 5.87 5.23 4.60 4.63 4.90
Research & Development Expense		 5.67 4.20 6.64 6.81 5.45 5.28 4.11 3.72 3.33 2.63 2.39
Total Other Income / (Expense), net		 -0.19 -0.01 8.69 2.58 -0.31 2.19 0.20 -3.79 -0.98 -0.39 0.00
Other Adjustments to Consolidated Net Income / (Loss)		 - - - - - - - - - - -0.88
Basic Earnings per Share		 ($0.49) ($0.41) $0.20 $0.08 $4.91 ($5.00) $2.87 $0.18 $2.96 ($2.57) ($1.25)
Weighted Average Basic Shares Outstanding		 28.82M 28.37M 34.44M 39.83M 2.02M 2.45M 2.37M 49.63M 3.14M 3.98M 6.58M
Diluted Earnings per Share		 ($0.49) ($0.41) $0.20 $0.08 $4.91 ($5.00) $2.87 $0.18 $2.96 ($2.57) ($1.25)
Weighted Average Diluted Shares Outstanding		 28.82M 28.37M 34.44M 39.83M 2.02M 2.45M 2.37M 49.63M 3.14M 3.98M 6.58M
Weighted Average Basic & Diluted Shares Outstanding		 27.21M 29.44M 29.92M 30.03M 34.10M 41.57M 43.95M 45.50M 6.77M 7.30M 7.31M

Annual Cash Flow Statements for DarioHealth

This table details how cash moves in and out of DarioHealth's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 1.22 -1.58 2.63 7.20 9.41 8.19 7.22 14 -13 -8.97 -5.97
Net Cash From Operating Activities		 -6.28 -8.38 -11 -11 -16 -18 -50 -48 -30 -39 -26
Net Cash From Continuing Operating Activities		 -6.28 -8.38 -11 -11 -16 -18 -50 -48 -30 -39 -26
Net Income / (Loss) Continuing Operations		 -7.14 -11 -16 -18 -18 -29 -77 -62 -59 -43 -42
Consolidated Net Income / (Loss)		 -7.14 -11 -16 -18 -18 -29 -77 -62 -59 -43 -42
Depreciation Expense		 0.34 0.39 0.20 0.21 0.18 0.19 0.28 0.36 0.47 1.33 0.31
Amortization Expense		 - - - - - 0.00 4.18 8.41 5.71 6.10 2.83
Non-Cash Adjustments To Reconcile Net Income		 0.50 1.45 4.91 3.76 2.63 9.98 25 17 18 -1.10 11
Changes in Operating Assets and Liabilities, net		 0.04 0.67 0.02 2.37 -0.80 1.54 -3.03 -11 4.39 -2.15 1.33
Net Cash From Investing Activities		 -0.11 -0.95 -0.22 -0.07 -0.11 -1.62 -8.13 -0.57 -0.55 -8.93 -4.34
Net Cash From Continuing Investing Activities		 -0.11 -0.95 -0.22 -0.07 -0.11 -1.62 -8.13 -0.57 -0.55 -8.93 -4.34
Purchase of Property, Plant & Equipment		 -0.11 -0.81 -0.20 -0.07 -0.10 -0.12 -0.26 -0.44 -0.58 -0.14 -0.14
Acquisitions		 - - - - - 0.00 -7.47 -0.13 0.00 -8.80 0.00
Purchase of Investments		 -0.28 -0.15 -0.02 - - -0.00 - 0.00 -5.00 0.00 -4.20
Net Cash From Financing Activities		 7.61 7.75 13 19 25 28 66 62 18 39 24
Net Cash From Continuing Financing Activities		 7.61 7.75 13 19 25 28 66 62 18 39 24
Repayment of Debt		 - - - - - - - 0.00 -28 0.00 -32
Issuance of Debt		 - - - - - - 0.00 24 30 0.00 32
Issuance of Preferred Equity		 - - - - - - - 0.00 15 39 6.75
Issuance of Common Equity		 7.08 7.54 13 19 25 28 65 38 1.61 0.00 17
Effect of Exchange Rate Changes		 - - - - - - - - 0.00 -0.07 0.01
Cash Interest Paid		 - - - - - - 0.00 1.88 4.03 3.93 3.49

Quarterly Cash Flow Statements for DarioHealth

This table details how cash moves in and out of DarioHealth's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -8.72 -7.42 -1.76 -11 -7.39 12 0.11 -5.95 10 -10 -6.85
Net Cash From Operating Activities		 -8.65 -7.34 -13 -11 -7.36 -6.73 -6.67 -6.03 -7.35 -5.89 -6.03
Net Cash From Continuing Operating Activities		 -8.40 -7.34 -13 -11 -7.36 -6.73 -6.67 -6.03 -7.35 -5.87 -6.00
Net Income / (Loss) Continuing Operations		 -16 -14 -7.18 -14 -12 -9.63 -9.23 -13 -10 -9.03 -8.25
Consolidated Net Income / (Loss)		 -16 -14 -7.18 -14 -12 -9.63 -9.23 -13 -10 -9.03 -8.25
Depreciation Expense		 0.10 0.18 0.11 0.54 0.13 0.55 0.09 0.08 0.07 0.06 0.06
Amortization Expense		 0.90 1.07 1.22 1.30 2.00 1.58 1.16 0.72 0.47 0.47 0.46
Non-Cash Adjustments To Reconcile Net Income		 5.54 3.47 -4.06 0.98 2.43 -0.44 1.82 4.63 3.06 1.82 1.67
Changes in Operating Assets and Liabilities, net		 0.79 2.23 -3.12 -0.65 0.41 1.21 -0.52 1.53 -0.49 0.81 0.05
Net Cash From Investing Activities		 -0.28 -0.08 -8.85 -0.03 -0.03 -0.02 -0.03 -0.04 -0.04 -4.23 -0.83
Net Cash From Continuing Investing Activities		 -0.28 -0.08 -8.85 -0.03 -0.03 -0.02 -0.03 -0.04 -0.04 -4.23 -0.83
Purchase of Property, Plant & Equipment		 -0.28 -0.08 -0.06 -0.03 -0.03 -0.02 -0.03 -0.04 -0.04 -0.03 -0.03
Purchase of Investments		 - - - - - - 0.00 - - - -5.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.01
Sale and/or Maturity of Investments		 - - - - - - 0.00 - - - 4.20
Net Cash From Financing Activities		 0.20 - 20 - - 18 6.82 0.12 17 -0.02 0.00
Net Cash From Continuing Financing Activities		 0.20 - 20 - - 18 6.82 0.12 17 -0.02 0.00
Issuance of Preferred Equity		 - - 20 - - 18 6.82 -0.06 - - 0.00
Effect of Exchange Rate Changes		 - - 0.00 -0.05 - - - - - - 0.03
Cash Interest Paid		 0.99 1.00 0.99 0.99 1.00 0.96 0.94 0.31 1.01 1.23 0.97

Annual Balance Sheets for DarioHealth

This table presents DarioHealth's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 5.08 3.87 6.96 14 25 35 101 119 96 119 110
Total Current Assets		 4.29 2.94 6.05 13 23 34 46 66 47 41 35
Cash & Equivalents		 2.67 1.09 3.72 11 20 29 36 49 37 28 22
Restricted Cash		 - - 0.26 0.18 0.19 0.19 0.19 0.17 0.29 0.18 0.23
Short-Term Investments		 0.08 0.23 - - - - - - - - 4.21
Accounts Receivable		 0.00 0.23 0.28 0.17 0.67 0.12 1.31 6.42 3.16 4.80 2.14
Inventories, net		 0.60 0.89 1.18 1.38 1.41 2.29 6.23 7.96 5.06 4.75 4.32
Prepaid Expenses		 0.94 0.50 0.60 0.38 0.27 2.93 2.07 1.63 2.02 2.34 2.36
Plant, Property, & Equipment, net		 0.75 0.90 0.87 0.73 0.65 0.58 0.70 0.79 0.90 0.71 0.55
Total Noncurrent Assets		 0.04 0.04 0.04 0.25 0.98 0.70 54 53 48 78 74
Goodwill		 - - - - - 0.00 42 42 42 57 57
Intangible Assets		 - - - - - 0.00 12 9.92 5.40 19 16
Other Noncurrent Operating Assets		 0.04 0.04 0.04 0.25 0.98 0.70 0.29 1.32 1.12 1.46 1.10
Total Liabilities & Shareholders' Equity		 5.08 3.87 6.96 14 25 35 101 119 96 119 110
Total Liabilities		 4.30 10 3.02 5.16 5.68 7.26 15 39 38 47 42
Total Current Liabilities		 1.69 2.93 3.02 5.16 5.22 7.03 14 19 12 17 9.32
Accounts Payable		 1.66 2.93 3.02 4.43 3.68 5.50 13 8.91 7.43 9.10 8.18
Current Deferred Revenue		 0.03 - 0.00 0.74 1.22 1.22 1.20 1.32 1.00 1.58 0.71
Other Current Liabilities		 - - - 0.00 0.32 0.31 0.27 0.29 0.11 0.50 0.43
Total Noncurrent Liabilities		 2.61 7.49 0.00 0.00 0.46 0.22 0.85 20 26 30 33
Long-Term Debt		 - - - - - - 0.00 18 25 23 31
Other Noncurrent Operating Liabilities		 2.61 7.49 0.00 0.00 0.46 0.22 0.85 1.74 1.16 6.76 2.08
Total Equity & Noncontrolling Interests		 -1.58 -6.54 3.94 8.93 19 28 86 80 58 72 68
Total Preferred & Common Equity		 -1.58 -6.54 3.94 8.93 19 28 86 80 58 72 68
Total Common Equity		 -1.58 -6.54 3.94 8.93 19 28 86 80 58 72 68
Common Stock		 42 48 75 98 129 171 308 366 408 462 520
Retained Earnings		 -43 -55 -71 -89 -110 -143 -222 -286 -349 -390 -452

Quarterly Balance Sheets for DarioHealth

This table presents DarioHealth's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 107 137 122 110 116 108 118 103
Total Current Assets		 56 53 39 30 39 32 42 29
Cash & Equivalents		 44 34 23 16 28 22 32 15
Restricted Cash		 0.40 0.97 0.86 0.86 0.19 0.22 0.22 0.25
Short-Term Investments		 - - - - - - - 5.04
Accounts Receivable		 4.53 7.89 6.73 4.95 3.21 2.56 2.38 2.22
Inventories, net		 5.47 4.92 5.13 4.74 4.62 4.61 4.87 4.17
Prepaid Expenses		 1.93 4.37 3.68 3.43 2.69 2.83 2.81 2.08
Plant, Property, & Equipment, net		 1.00 1.43 1.33 1.24 0.65 0.61 0.58 0.51
Total Noncurrent Assets		 49 83 81 79 76 76 75 74
Goodwill		 42 57 57 57 57 57 57 57
Intangible Assets		 6.54 24 22 20 18 17 16 15
Other Noncurrent Operating Assets		 1.11 1.96 1.69 1.42 1.37 1.24 1.13 1.14
Total Liabilities & Shareholders' Equity		 107 137 122 110 116 108 118 103
Total Liabilities		 38 59 54 51 42 44 43 41
Total Current Liabilities		 8.11 18 17 19 19 9.75 9.28 9.36
Accounts Payable		 7.30 11 9.83 8.46 7.07 8.52 7.98 8.48
Current Deferred Revenue		 0.68 1.79 1.52 1.12 1.31 0.73 0.86 0.50
Other Current Liabilities		 0.12 0.92 0.88 0.60 0.49 0.51 0.44 0.38
Total Noncurrent Liabilities		 30 41 37 33 23 35 34 32
Long-Term Debt		 29 25 23 20 19 30 31 31
Other Noncurrent Operating Liabilities		 1.36 17 13 12 3.85 4.09 2.90 0.61
Total Equity & Noncontrolling Interests		 68 78 68 59 74 64 75 62
Total Preferred & Common Equity		 68 78 68 59 74 64 75 62
Total Common Equity		 68 78 68 59 74 64 75 62
Common Stock		 402 437 432 437 478 487 517 523
Retained Earnings		 -334 -359 -363 -378 -404 -423 -442 -460

Annual Metrics And Ratios for DarioHealth

This table displays calculated financial ratios and metrics derived from DarioHealth's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 42,993,162.00 5,713,383.00 20,704,848.00 25,936,165.00 43,696,840.00 8,114,360.00 16,575,633.00 23,296,754.00 27,214,670.00 34,096,355.00 6,768,184.00
DEI Adjusted Shares Outstanding		 5,971.00 14,283.00 51,762.00 64,840.00 109,242.00 405,718.00 828,782.00 1,164,838.00 1,360,734.00 1,704,818.00 6,768,184.00
DEI Earnings Per Adjusted Shares Outstanding		 -1,221.91 -812.64 -309.07 -282.17 -191.24 -81.59 -95.04 -54.80 -46.67 -24.04 -9.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 1,513.73% 240.58% 84.45% 43.02% 2.23% 0.22% 170.76% 34.82% -26.41% 32.86% -17.31%
EBITDA Growth		 44.78% -54.25% -48.08% -13.17% 0.42% -66.96% -146.24% 25.84% 0.45% 30.10% 4.63%
EBIT Growth		 44.54% -52.44% -44.60% -13.09% 0.55% -66.31% -159.79% 18.70% 4.54% 24.87% 13.48%
NOPAT Growth		 32.22% -44.21% -29.89% -22.67% -0.10% -68.90% -155.81% 25.73% 1.09% -2.77% 36.52%
Net Income Growth		 44.54% -52.44% -44.60% -13.09% 0.38% -66.02% -160.69% 18.98% 4.45% 28.07% 2.42%
EPS Growth		 44.54% 45.57% 21.53% -13.09% 48.82% 49.88% -1.50% 37.59% 24.02% 28.07% -17.52%
Operating Cash Flow Growth		 26.85% -33.49% -26.73% -8.01% -37.10% -12.79% -184.22% 5.09% 36.51% -26.94% 32.73%
Free Cash Flow Firm Growth		 -16.69% 74.82% -850.17% 43.27% -27.44% -69.82% -371.15% 53.98% 33.91% -102.44% 60.71%
Invested Capital Growth		 51.55% -298.13% 99.55% -6,334.29% 24.87% 63.00% 8,002.88% 16.04% -13.60% 47.18% -0.79%
Revenue Q/Q Growth		 45.41% 23.32% 16.70% 1.68% 1.31% 3.87% 23.83% 2.91% -13.56% 17.30% -9.59%
EBITDA Q/Q Growth		 21.73% -25.79% 3.19% -10.77% 4.07% -17.80% -19.54% 17.97% -30.50% 13.15% 0.77%
EBIT Q/Q Growth		 20.93% -25.04% 3.59% -10.68% 4.04% -17.69% -19.72% 10.47% -16.43% 9.61% 5.84%
NOPAT Q/Q Growth		 8.53% -21.60% 4.74% -11.39% 4.04% -19.52% -19.72% 18.22% -10.21% 4.22% 7.81%
Net Income Q/Q Growth		 20.93% -25.04% 3.59% -10.68% 4.37% -19.59% -19.62% 12.60% -2.89% 9.82% 1.42%
EPS Q/Q Growth		 20.93% -26.67% 0.00% -10.68% -9.44% 4.52% -0.99% 20.13% 0.52% 9.82% 149.83%
Operating Cash Flow Q/Q Growth		 5.28% 2.38% -5.33% -10.00% 3.60% -28.26% -19.93% 13.07% 1.94% 1.55% 3.15%
Free Cash Flow Firm Q/Q Growth		 -31.31% 82.49% -90.30% 1.35% 2.22% -34.72% -4.02% 10.42% -1.79% -5.67% 17.22%
Invested Capital Q/Q Growth		 45.01% -1,092.30% 90.98% -87.67% -95.16% 69.49% -6.40% -0.13% -5.99% 2.88% -1.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 -103.89% -29.61% 25.36% 23.87% 34.36% 33.17% 19.32% 34.91% 29.40% 49.06% 56.64%
EBITDA Margin		 -827.10% -374.60% -300.74% -237.98% -231.80% -386.15% -351.18% -193.16% -261.30% -137.47% -158.55%
Operating Margin		 -935.36% -396.04% -278.90% -239.22% -234.22% -394.71% -372.91% -205.42% -276.09% -213.55% -163.94%
EBIT Margin		 -867.80% -388.41% -304.51% -240.78% -234.22% -388.66% -372.91% -224.87% -291.68% -164.94% -172.59%
Profit (Net Income) Margin		 -867.80% -388.41% -304.51% -240.78% -234.63% -388.66% -374.21% -224.88% -292.00% -158.09% -186.56%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.18% 100.00% 100.04% 100.01% 100.11% 95.85% 100.25%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.31% 100.00% 100.00% 100.00% 107.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -219.24% -74.42% -73.51% -65.94% -35.29%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -147.65% 2.03% 55.55% -4.40% -620.72%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 84.22% -0.72% -12.52% 0.26% -24.33%
Return on Equity (ROE)		 811.13% 377.76% 1,211.00% -276.74% -127.51% -125.18% -135.02% -75.14% -86.04% -65.68% -59.62%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -209.50% -89.26% -58.93% -104.11% -34.49%
Operating Return on Assets (OROA)		 -175.09% -243.31% -290.76% -169.18% -91.60% -98.19% -112.34% -56.55% -55.07% -41.43% -33.71%
Return on Assets (ROA)		 -175.09% -243.31% -290.76% -169.18% -91.76% -98.19% -112.74% -56.55% -55.13% -39.71% -36.44%
Return on Common Equity (ROCE)		 3,166.68% 532.23% 1,211.00% -276.74% -127.51% -125.18% -135.02% -75.14% -86.04% -65.68% -59.62%
Return on Equity Simple (ROE_SIMPLE)		 452.03% 166.44% -399.47% -199.47% -93.87% -104.60% -89.73% -77.74% -102.21% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.39 -7.77 -10 -12 -12 -21 -54 -40 -39 -40 -26
NOPAT Margin		 -654.75% -277.23% -195.23% -167.45% -163.96% -276.29% -261.03% -143.79% -193.26% -149.49% -114.76%
Net Nonoperating Expense Percent (NNEP)		 -81.80% -153.17% -213.44% -71.56% -33.64% -34.49% -71.59% -76.45% -129.07% -61.54% 585.43%
Return On Investment Capital (ROIC_SIMPLE)		 341.05% 118.80% -256.11% -138.73% -65.59% -74.36% -62.59% -37.19% -45.37% -40.04% -26.00%
Cost of Revenue to Revenue		 203.89% 129.61% 74.64% 76.13% 65.64% 66.83% 80.68% 65.09% 70.60% 50.94% 43.36%
SG&A Expenses to Revenue		 358.20% 120.51% 91.41% 73.95% 72.54% 168.37% 114.72% 59.64% 89.13% 75.75% 67.94%
R&D to Revenue		 311.66% 76.85% 63.77% 49.72% 48.84% 58.51% 83.94% 71.05% 99.49% 89.42% 61.68%
Operating Expenses to Revenue		 831.47% 366.43% 304.26% 263.09% 268.58% 427.88% 392.22% 240.33% 305.49% 262.61% 220.58%
Earnings before Interest and Taxes (EBIT)		 -7.14 -11 -16 -18 -18 -29 -76 -62 -59 -45 -39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -6.81 -11 -16 -18 -18 -29 -72 -53 -53 -37 -35
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.21 2.26 0.76 4.12 2.51 1.25 0.81 0.37 1.13
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.21 2.26 0.76 4.12 6.84 3.51 4.22 0.00 0.00
Price to Revenue (P/Rev)		 49.63 6.62 3.21 2.72 1.90 15.31 10.48 3.61 2.30 0.99 3.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 3.62 1.34 0.77 0.38 1.13
Enterprise Value to Revenue (EV/Rev)		 49.15 6.15 2.44 1.21 0.00 11.51 8.73 2.79 1.88 1.03 3.65
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.34 0.49 0.40 0.45
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.23 0.42 0.33 0.45
Financial Leverage		 2.43 0.71 2.04 -1.18 -1.14 -1.05 -0.57 -0.35 -0.23 -0.06 0.04
Leverage Ratio		 -4.63 -1.55 -4.17 1.64 1.39 1.27 1.20 1.33 1.56 1.65 1.64
Compound Leverage Factor		 -4.63 -1.55 -4.17 1.64 1.39 1.27 1.20 1.33 1.56 1.65 1.76
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 25.18% 32.93% 28.65% 31.16%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.25% 4.56% 5.40% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 16.93% 28.37% 23.25% 31.16%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 303.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -203.35% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 74.82% 67.07% 71.35% 68.84%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.50 -0.54 -0.78 -0.87
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.42 0.16 -0.03 -0.13
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.34 -0.46 -0.63 -0.87
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.68 -0.73 -0.72 -1.20
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.57 0.22 -0.02 -0.18
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.46 -0.63 -0.58 -1.20
Altman Z-Score		 -10.12 -27.35 -17.18 -9.50 -5.97 2.31 3.46 -2.86 -5.73 -5.02 -5.33
Noncontrolling Interest Sharing Ratio		 -290.40% -40.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.54 1.00 2.01 2.54 4.39 4.85 3.17 3.39 3.79 2.44 3.76
Quick Ratio		 1.63 0.53 1.33 2.16 4.04 4.08 2.58 2.88 3.20 1.96 3.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -7.49 -1.89 -18 -10 -13 -22 -104 -48 -32 -64 -25
Operating Cash Flow to CapEx		 -5,706.36% -1,037.01% -5,445.64% -16,154.93% -16,045.92% -15,030.51% -19,313.79% -10,824.66% -5,201.88% -27,943.48% -18,268.31%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.30
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.59
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.64
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.20 0.63 0.95 0.70 0.39 0.25 0.30 0.25 0.19 0.25 0.20
Accounts Receivable Turnover		 0.00 0.00 20.35 32.86 18.00 19.04 28.61 7.16 4.25 6.79 6.44
Inventory Turnover		 4.02 4.88 3.72 4.40 3.56 2.73 3.88 2.54 2.21 2.81 2.14
Fixed Asset Turnover		 0.95 3.40 5.84 9.23 10.95 12.38 32.10 37.12 24.13 33.63 35.55
Accounts Payable Turnover		 1.03 1.59 1.30 1.51 1.22 1.10 1.80 1.65 1.76 1.67 1.12
Days Sales Outstanding (DSO)		 0.00 0.00 17.93 11.11 20.28 19.18 12.76 50.98 85.82 53.72 56.71
Days Inventory Outstanding (DIO)		 90.82 74.80 97.99 83.03 102.65 133.62 93.96 143.80 165.35 130.05 170.73
Days Payable Outstanding (DPO)		 353.58 230.27 280.91 241.31 298.21 330.90 203.07 221.31 207.61 219.01 325.24
Cash Conversion Cycle (CCC)		 -262.77 -155.47 -164.99 -147.17 -175.28 -178.10 -96.35 -26.52 43.57 -35.23 -97.79
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.97 -7.86 -0.04 -2.25 -1.69 -0.63 49 57 50 73 72
Invested Capital Turnover		 -0.27 -0.57 -1.31 -6.47 -3.83 -6.54 0.84 0.52 0.38 0.44 0.31
Increase / (Decrease) in Invested Capital		 2.10 -5.89 7.82 -2.22 0.56 1.07 50 7.93 -7.81 23 -0.58
Enterprise Value (EV)		 40 17 13 8.95 -6.25 87 179 77 38 28 82
Market Capitalization		 41 19 17 20 14 116 215 100 47 27 77
Book Value per Share		 ($0.04) ($1.14) $0.38 $0.34 $0.43 $3.47 $5.16 $3.43 $2.14 $2.11 $10.04
Tangible Book Value per Share		 ($0.04) ($1.14) $0.38 $0.34 $0.43 $3.47 $1.90 $1.22 $0.41 ($0.12) ($0.80)
Total Capital		 0.78 -6.54 3.94 8.93 19 28 86 107 87 101 99
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 27 29 29 31
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 18 25 23 31
Net Debt		 -2.75 -1.32 -3.98 -11 -21 -29 -36 -23 -8.54 0.98 4.50
Capital Expenditures (CapEx)		 0.11 0.81 0.20 0.07 0.10 0.12 0.26 0.44 0.58 0.14 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.15 -1.31 -0.95 -3.24 -2.87 -1.68 -4.77 5.48 1.70 1.41 -0.50
Debt-free Net Working Capital (DFNWC)		 2.60 0.01 3.03 7.94 18 27 31 55 39 29 26
Net Working Capital (NWC)		 2.60 0.01 3.03 7.94 18 27 31 46 35 24 26
Net Nonoperating Expense (NNE)		 1.75 3.12 5.65 5.42 5.34 8.51 23 22 20 2.33 16
Net Nonoperating Obligations (NNO)		 -2.75 -1.32 -3.98 -11 -21 -29 -36 -23 -8.54 0.98 4.50
Total Depreciation and Amortization (D&A)		 0.34 0.39 0.20 0.21 0.18 0.19 4.46 8.77 6.18 7.43 3.14
Debt-free, Cash-free Net Working Capital to Revenue		 -18.71% -46.63% -18.28% -43.81% -37.93% -22.21% -23.26% 19.80% 8.36% 5.20% -2.25%
Debt-free Net Working Capital to Revenue		 315.55% 0.39% 58.63% 107.36% 234.41% 357.63% 152.24% 198.86% 190.60% 108.52% 115.14%
Net Working Capital to Revenue		 315.55% 0.39% 58.63% 107.36% 234.41% 357.63% 152.24% 166.96% 171.17% 88.37% 115.14%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($75.60) ($41.80) ($32.80) ($15.60) ($8.00) ($4.01) ($4.07) ($2.54) ($1.93) ($12.20) $10.12
Adjusted Weighted Average Basic Shares Outstanding		 148.61K 398.83K 822.40K 1.84M 3.10M 15.27M 16.59M 23.64M 28.37M 2.45M 3.98M
Adjusted Diluted Earnings per Share		 ($75.60) ($41.80) ($32.80) ($15.60) ($8.00) ($4.01) ($4.07) ($2.54) ($1.93) ($12.20) $10.12
Adjusted Weighted Average Diluted Shares Outstanding		 148.61K 398.83K 822.40K 1.84M 3.10M 15.27M 16.59M 23.64M 28.37M 2.45M 3.98M
Adjusted Basic & Diluted Earnings per Share		 ($75.60) ($41.80) ($32.80) ($15.60) ($8.00) ($4.01) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 94.89K 260.15K 481.41K 1.17M 2.27M 5.96M 21.81M 25.87M 29.44M 2.08M 7.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.39 -7.77 -10 -12 -12 -21 -54 -40 -39 -40 -26
Normalized NOPAT Margin		 -654.75% -277.23% -195.23% -167.45% -163.96% -276.29% -261.03% -143.79% -193.26% -149.49% -114.76%
Pre Tax Income Margin		 -867.80% -388.41% -304.51% -240.78% -234.22% -388.66% -374.05% -224.87% -291.68% -164.94% -186.10%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.78
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.50
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -12.82
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.54
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.22% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for DarioHealth

This table displays calculated financial ratios and metrics derived from DarioHealth's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 27,229,544.00 27,214,670.00 29,442,532.00 29,923,250.00 30,028,280.00 34,096,355.00 41,567,016.00 43,949,424.00 45,496,954.00 6,768,184.00 7,300,406.00
DEI Adjusted Shares Outstanding		 1,361,477.00 1,360,734.00 1,472,127.00 1,496,163.00 1,501,414.00 1,704,818.00 2,078,351.00 2,197,471.00 2,274,848.00 6,768,184.00 7,300,406.00
DEI Earnings Per Adjusted Shares Outstanding		 -12.42 -11.40 -6.26 -3.28 -9.73 -7.19 -6.77 -8.45 -8.29 -1.51 -1.13
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -46.74% -46.89% -18.51% 1.67% 111.00% 110.29% 17.26% -14.16% -32.55% -31.21% -17.30%
EBITDA Growth		 -2.25% -249.78% 32.48% 15.10% 30.65% 43.39% -1.35% -3.53% 14.21% 10.77% 14.64%
EBIT Growth		 -0.64% -57.84% 28.51% 17.94% 21.54% 33.36% -0.39% 4.56% 24.58% 25.24% 20.60%
NOPAT Growth		 -6.68% -57.77% -43.90% -15.49% 22.62% 17.92% 47.30% 43.18% 21.16% 26.62% 22.32%
Net Income Growth		 -0.64% -13.22% 44.05% 17.94% 21.62% 32.57% -28.60% 4.56% 15.12% 6.24% 10.60%
EPS Growth		 23.44% 2.38% 144.44% 113.79% 21.62% 32.57% -28.60% 125.00% -39.71% 48.60% -143.55%
Operating Cash Flow Growth		 19.17% 7.56% -175.59% -17.92% 14.90% 8.30% 49.10% 46.92% 0.10% 12.55% 9.71%
Free Cash Flow Firm Growth		 58.40% 84.93% -656.35% -273.08% -331.66% -1,371.48% 65.30% 80.27% 65.80% 82.85% 67.73%
Invested Capital Growth		 -8.20% -13.60% 31.67% 33.73% 34.49% 47.18% 5.19% -0.79% 3.47% -0.79% -2.40%
Revenue Q/Q Growth		 -42.82% 2.79% 59.24% 8.63% 18.67% 2.44% -11.20% -20.48% -6.74% 4.47% 6.75%
EBITDA Q/Q Growth		 -6.24% 11.95% 39.53% -50.10% 13.23% 28.13% -8.27% -53.33% 28.10% 25.24% -3.57%
EBIT Q/Q Growth		 5.14% 9.60% 35.52% -48.43% 9.31% 23.22% 2.87% -41.12% 28.34% 23.89% -3.16%
NOPAT Q/Q Growth		 -10.88% 8.56% -25.61% 9.32% 25.70% 3.01% 19.36% 2.22% -3.09% 9.72% 14.63%
Net Income Q/Q Growth		 5.14% 9.20% 49.77% -89.69% 9.40% 21.88% 4.20% -40.78% 19.43% 13.71% 8.66%
EPS Q/Q Growth		 15.52% 16.33% 148.78% -60.00% 9.40% 21.88% 4.20% 28.57% 1,544.44% -186.82% 51.36%
Operating Cash Flow Q/Q Growth		 10.28% 15.08% -78.59% 13.33% 35.25% 8.50% 0.88% 9.62% -21.87% 19.90% -2.34%
Free Cash Flow Firm Q/Q Growth		 22.59% 65.21% -1,280.35% -0.35% 10.44% -18.61% 67.45% 42.94% -55.23% 40.53% 38.74%
Invested Capital Q/Q Growth		 -3.19% -5.99% 43.46% 2.43% -2.65% 2.88% 2.53% -3.39% 1.53% -1.36% 0.86%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 17.34% 3.65% 42.24% 44.06% 52.23% 55.26% 57.49% 55.21% 60.22% 53.60% 57.31%
EBITDA Margin		 -418.70% -358.68% -136.21% -188.20% -137.61% -96.55% -117.73% -227.01% -175.02% -125.23% -121.51%
Operating Margin		 -441.90% -393.11% -310.09% -258.85% -162.06% -153.45% -139.35% -171.35% -189.41% -163.68% -130.89%
EBIT Margin		 -447.19% -393.28% -159.24% -217.59% -166.28% -124.63% -136.33% -241.94% -185.92% -135.44% -130.89%
Profit (Net Income) Margin		 -447.19% -395.05% -124.61% -217.59% -166.11% -126.67% -136.66% -241.94% -209.03% -172.64% -147.73%
Tax Burden Percent		 100.00% 100.45% 78.25% 100.00% 99.89% 101.64% 100.24% 100.00% 100.00% 100.93% 112.86%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 112.43% 126.30% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -132.13% -104.68% -66.04% -54.47% -42.27% -47.38% -37.46% -44.85% -45.42% -35.23% -26.26%
ROIC Less NNEP Spread (ROIC-NNEP)		 -111.38% -76.84% -108.85% -30.59% 234.37% -8.64% 54.74% -144.39% -115.42% -145.99% -79.29%
Return on Net Nonoperating Assets (RNNOA)		 33.16% 17.32% 18.04% 3.98% -5.23% 0.50% -2.07% -14.39% -9.46% -5.72% -6.88%
Return on Equity (ROE)		 -98.97% -87.36% -48.00% -50.48% -47.51% -46.88% -39.53% -59.24% -54.88% -40.95% -33.14%
Cash Return on Invested Capital (CROIC)		 -56.19% -58.93% -96.27% -98.99% -97.64% -104.11% -52.33% -40.00% -41.97% -34.49% -30.28%
Operating Return on Assets (OROA)		 -90.44% -74.26% -24.76% -34.82% -35.42% -31.31% -30.26% -57.00% -40.39% -26.45% -25.34%
Return on Assets (ROA)		 -90.44% -74.59% -19.37% -34.82% -35.38% -31.82% -30.34% -57.00% -45.41% -33.72% -28.60%
Return on Common Equity (ROCE)		 -98.97% -87.36% -48.00% -50.48% -47.51% -46.88% -39.53% -59.24% -54.88% -40.95% -33.14%
Return on Equity Simple (ROE_SIMPLE)		 -84.90% 0.00% -68.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 -9.95 -12 -11 -8.42 -8.17 -6.59 -6.44 -6.64 -5.99 -5.12
NOPAT Margin		 -309.33% -275.18% -217.06% -181.19% -113.44% -107.41% -97.55% -119.95% -132.59% -114.57% -91.62%
Net Nonoperating Expense Percent (NNEP)		 -20.75% -27.84% 42.82% -23.88% -276.65% -38.74% -92.20% 99.54% 70.00% 110.76% 53.03%
Return On Investment Capital (ROIC_SIMPLE)		 -11.21% -11.48% -11.74% -11.72% -9.64% -8.09% -6.40% -6.82% -6.29% -6.07% -5.48%
Cost of Revenue to Revenue		 82.66% 96.35% 57.76% 55.94% 47.77% 44.74% 42.51% 44.79% 39.78% 46.40% 42.69%
SG&A Expenses to Revenue		 117.34% 152.90% 116.97% 80.02% 50.22% 65.94% 49.02% 59.82% 91.21% 78.42% 57.77%
R&D to Revenue		 161.03% 116.04% 115.35% 108.87% 73.37% 69.45% 60.84% 69.31% 66.47% 50.35% 42.71%
Operating Expenses to Revenue		 459.24% 396.76% 352.33% 302.91% 214.29% 208.71% 196.85% 226.56% 249.63% 217.28% 188.20%
Earnings before Interest and Taxes (EBIT)		 -16 -14 -9.17 -14 -12 -9.48 -9.21 -13 -9.31 -7.09 -7.31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -15 -13 -7.84 -12 -10 -7.34 -7.95 -12 -8.76 -6.55 -6.79
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.31 0.81 0.58 0.52 0.57 0.37 0.35 0.46 0.53 1.13 0.94
Price to Tangible Book Value (P/TBV)		 4.50 4.22 0.00 0.00 0.00 0.00 0.00 0.00 35.82 0.00 0.00
Price to Revenue (P/Rev)		 3.79 2.30 2.37 1.86 1.46 0.99 0.91 1.08 1.60 3.44 2.76
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.40 0.77 0.54 0.55 0.65 0.38 0.36 0.52 0.52 1.13 0.95
Enterprise Value to Revenue (EV/Rev)		 3.14 1.88 2.00 2.11 2.00 1.03 0.95 1.39 1.53 3.65 3.27
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.43 0.49 0.36 0.42 0.49 0.40 0.40 0.48 0.41 0.45 0.50
Long-Term Debt to Equity		 0.43 0.42 0.31 0.34 0.35 0.33 0.26 0.48 0.41 0.45 0.50
Financial Leverage		 -0.30 -0.23 -0.17 -0.13 -0.02 -0.06 -0.04 0.10 0.08 0.04 0.09
Leverage Ratio		 1.48 1.56 1.63 1.63 1.71 1.65 1.66 1.75 1.71 1.64 1.61
Compound Leverage Factor		 1.48 1.56 1.63 1.63 1.71 1.65 1.66 1.75 1.92 2.07 1.61
Debt to Total Capital		 29.89% 32.93% 26.73% 29.61% 33.03% 28.65% 28.37% 32.28% 29.01% 31.16% 33.15%
Short-Term Debt to Total Capital		 0.00% 4.56% 3.71% 5.37% 9.92% 5.40% 10.01% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 29.89% 28.37% 23.01% 24.24% 23.11% 23.25% 18.37% 32.28% 29.01% 31.16% 33.15%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 70.11% 67.07% 73.27% 70.39% 66.97% 71.35% 71.63% 67.72% 70.99% 68.84% 66.85%
Debt to EBITDA		 -0.71 -0.54 -0.58 -0.61 -0.67 -0.78 -0.78 -0.82 -0.86 -0.87 -0.96
Net Debt to EBITDA		 0.37 0.16 0.14 -0.10 -0.29 -0.03 -0.03 -0.22 0.04 -0.13 -0.33
Long-Term Debt to EBITDA		 -0.71 -0.46 -0.50 -0.50 -0.47 -0.63 -0.51 -0.82 -0.86 -0.87 -0.96
Debt to NOPAT		 -0.81 -0.73 -0.66 -0.64 -0.68 -0.72 -0.85 -1.03 -1.10 -1.20 -1.28
Net Debt to NOPAT		 0.43 0.22 0.16 -0.11 -0.29 -0.02 -0.03 -0.28 0.05 -0.18 -0.44
Long-Term Debt to NOPAT		 -0.81 -0.63 -0.57 -0.52 -0.48 -0.58 -0.55 -1.03 -1.10 -1.20 -1.28
Altman Z-Score		 -2.72 -4.18 -2.98 -3.77 -4.47 -4.05 -4.35 -4.96 -4.42 -4.38 -5.18
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.93 3.79 2.95 2.26 1.57 2.44 2.01 3.30 4.55 3.76 3.07
Quick Ratio		 5.97 3.20 2.37 1.70 1.09 1.96 1.62 2.51 3.69 3.02 2.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -6.17 -2.15 -30 -30 -27 -32 -10 -5.86 -9.10 -5.41 -3.32
Operating Cash Flow to CapEx		 -3,076.51% -8,844.58% -23,410.71% -39,182.76% -22,990.63% -32,057.14% -21,525.81% -13,706.82% -17,926.83% -22,642.31% -23,173.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -7.87 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6.35 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -6.39 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.20 0.19 0.16 0.16 0.21 0.25 0.22 0.24 0.22 0.20 0.19
Accounts Receivable Turnover		 5.20 4.25 3.57 3.31 4.86 6.79 5.05 5.85 6.75 6.44 7.81
Inventory Turnover		 2.26 2.21 2.34 2.39 2.71 2.81 2.79 2.51 2.22 2.14 2.09
Fixed Asset Turnover		 25.36 24.13 17.39 17.80 20.64 33.63 27.07 27.93 27.28 35.55 36.63
Accounts Payable Turnover		 1.89 1.76 1.46 1.56 1.76 1.67 1.46 1.33 1.30 1.12 1.18
Days Sales Outstanding (DSO)		 70.18 85.82 102.37 110.11 75.06 53.72 72.21 62.43 54.04 56.71 46.73
Days Inventory Outstanding (DIO)		 161.42 165.35 156.00 152.54 134.53 130.05 130.71 145.46 164.40 170.73 174.29
Days Payable Outstanding (DPO)		 192.70 207.61 250.75 234.29 207.66 219.01 249.45 273.88 281.20 325.24 308.06
Cash Conversion Cycle (CCC)		 38.90 43.57 7.62 28.35 1.93 -35.23 -46.53 -65.99 -62.76 -97.79 -87.03
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 53 50 71 73 71 73 75 72 73 72 73
Invested Capital Turnover		 0.43 0.38 0.30 0.30 0.37 0.44 0.38 0.37 0.34 0.31 0.29
Increase / (Decrease) in Invested Capital		 -4.72 -7.81 17 18 18 23 3.69 -0.58 2.46 -0.58 -1.80
Enterprise Value (EV)		 74 38 38 40 46 28 27 38 38 82 69
Market Capitalization		 89 47 45 36 34 27 25 29 39 77 59
Book Value per Share		 $2.50 $2.14 $2.65 $2.27 $1.95 $2.11 $1.77 $1.46 $1.65 $10.04 $8.54
Tangible Book Value per Share		 $0.73 $0.41 ($0.10) ($0.39) ($0.64) ($0.12) ($0.03) ($0.23) $0.02 ($0.80) ($1.44)
Total Capital		 97 87 106 97 87 101 103 94 106 99 93
Total Debt		 29 29 28 29 29 29 29 30 31 31 31
Total Long-Term Debt		 29 25 25 23 20 23 19 30 31 31 31
Net Debt		 -15 -8.54 -6.88 4.83 12 0.98 1.15 8.33 -1.51 4.50 11
Capital Expenditures (CapEx)		 0.28 0.08 0.06 0.03 0.03 0.02 0.03 0.04 0.04 0.03 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.83 1.70 3.32 3.32 2.94 1.41 1.66 0.24 0.78 -0.50 -0.89
Debt-free Net Working Capital (DFNWC)		 48 39 39 27 19 29 30 22 33 26 19
Net Working Capital (NWC)		 48 35 35 22 11 24 19 22 33 26 19
Net Nonoperating Expense (NNE)		 4.85 4.33 -5.32 2.28 3.91 1.46 2.64 6.55 3.83 3.04 3.13
Net Nonoperating Obligations (NNO)		 -15 -8.54 -6.88 4.83 12 0.98 1.15 8.33 -1.51 4.50 11
Total Depreciation and Amortization (D&A)		 1.00 1.25 1.33 1.84 2.13 2.14 1.26 0.80 0.55 0.53 0.52
Debt-free, Cash-free Net Working Capital to Revenue		 16.28% 8.36% 17.45% 17.33% 12.76% 5.20% 5.91% 0.90% 3.14% -2.25% -4.19%
Debt-free Net Working Capital to Revenue		 204.31% 190.60% 203.01% 141.61% 83.95% 108.52% 105.95% 82.57% 133.05% 115.14% 91.44%
Net Working Capital to Revenue		 204.31% 171.17% 182.25% 114.50% 46.34% 88.37% 69.23% 82.57% 133.05% 115.14% 91.44%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.49) ($0.41) ($0.20) ($0.08) ($5.00) ($100.00) $2.80 $0.18 $2.96 ($2.57) ($1.25)
Adjusted Weighted Average Basic Shares Outstanding		 28.82M 28.37M 34.44M 39.83M 2.02M 122.60K 2.37M 49.63M 3.14M 3.98M 6.58M
Adjusted Diluted Earnings per Share		 ($0.49) ($0.41) ($0.20) ($0.08) ($5.00) ($100.00) $2.80 $0.18 $2.96 ($2.57) ($1.25)
Adjusted Weighted Average Diluted Shares Outstanding		 28.82M 28.37M 34.44M 39.83M 2.02M 122.60K 2.37M 49.63M 3.14M 3.98M 6.58M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($100.00) $0.00 $0.00 $0.00 ($2.57) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 27.21M 29.44M 29.92M 30.03M 1.70M 2.08M 2.20M 45.50M 6.77M 7.30M 7.31M
Normalized Net Operating Profit after Tax (NOPAT)		 -11 -9.95 -12 -11 -8.42 -8.17 -6.59 -6.44 -6.64 -5.99 -5.12
Normalized NOPAT Margin		 -309.33% -275.18% -217.06% -181.19% -113.44% -107.41% -97.55% -119.95% -132.59% -114.57% -91.62%
Pre Tax Income Margin		 -447.19% -393.28% -159.24% -217.59% -166.28% -124.63% -136.33% -241.94% -209.03% -171.06% -130.89%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.05 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.74 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -8.08 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -5.77 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

DarioHealth Financials - Frequently Asked Questions

According to the most recent income statement we have on file, DarioHealth's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

DarioHealth's net income appears to be on an upward trend, with a most recent value of -$41.71 million in 2025, rising from -$7.14 million in 2015. The previous period was -$42.75 million in 2024. View DarioHealth's forecast to see where analysts expect DarioHealth to go next.

DarioHealth's total operating income in 2025 was -$36.66 million, based on the following breakdown:
  • Total Gross Profit: $12.67 million
  • Total Operating Expenses: $49.32 million

Over the last 10 years, DarioHealth's total revenue changed from $823 thousand in 2015 to $22.36 million in 2025, a change of 2,616.8%.

DarioHealth's total liabilities were at $42.15 million at the end of 2025, a 10.1% decrease from 2024, and a 880.3% increase since 2015.

In the past 10 years, DarioHealth's cash and equivalents has ranged from $1.09 million in 2016 to $49.36 million in 2022, and is currently $21.80 million as of their latest financial filing in 2025.

Over the last 10 years, DarioHealth's book value per share changed from -0.04 in 2015 to 10.04 in 2025, a change of -27,370.4%.


Related Companies

Financial statements for NASDAQ:DRIO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Porter flew 3,300 miles to investigate this system
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel